+Compare
VNDA
Stock ticker: NASDAQ
AS OF
Loading...
Price
Loading...
Change
Loading...
Capitalization
204.81M

VNDA Vanda Pharmaceuticals Forecast, Technical & Fundamental Analysis

a manufacturer of biopharmaceutical products

Industry Biotechnology
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
A.I.Advisor
a Summary for VNDA with price predictions
07:00 PM EST Dec 04, 2023

Momentum Indicator for VNDA turns positive, indicating new upward trend

VNDA saw its Momentum Indicator move above the 0 level on November 24, 2023. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 99 similar instances where the indicator turned positive. In of the 99 cases, the stock moved higher in the following days. The odds of a move higher are at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where VNDA's RSI Oscillator exited the oversold zone, of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for VNDA just turned positive on November 28, 2023. Looking at past instances where VNDA's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VNDA advanced for three days, in of 266 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VNDA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VNDA broke above its upper Bollinger Band on December 05, 2023. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

Fear & Greed

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.376) is normal, around the industry mean (20.669). P/E Ratio (16.892) is within average values for comparable stocks, (137.286). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (7.704). Dividend Yield (0.000) settles around the average of (0.035) among similar stocks. P/S Ratio (0.969) is also within normal values, averaging (329.913).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. VNDA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VNDA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Sarepta Therapeutics (NASDAQ:SRPT), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sorrento Therapeutics, Inc. (OTC:SRNEQ).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 402 to 464.61B. NVO holds the highest valuation in this group at 464.61B. The lowest valued company is PNEXF at 402.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 11%. For the same Industry, the average monthly price growth was 25%, and the average quarterly price growth was 26%. CMND experienced the highest price growth at 3,849%, while BRRGF experienced the biggest fall at -99%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -18%. For the same stocks of the Industry, the average monthly volume growth was -41% and the average quarterly volume growth was 8%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 85
Price Growth Rating: 64
SMR Rating: 94
Profit Risk Rating: 94
Seasonality Score: 26 (-100 ... +100)
View a ticker or compare two or three
Technical Analysis# Of IndicatorsAvg. Odds
   
   
Show details...
Ad is loading...
A.I. Advisor
published Earnings

VNDA is expected to report earnings to fall ∞% to -2 cents per share on February 14

Vanda Pharmaceuticals VNDA Stock Earnings Reports
Q4'23
Est.
$-0.03
Q3'23
Beat
by $0.04
Q2'23
Missed
by $0.05
Q4'22
Beat
by $0.04
Q3'22
Missed
by $0.04
The last earnings report on November 08 showed earnings per share of 0 cents, beating the estimate of -3 cents. With 566.35K shares outstanding, the current market capitalization sits at 204.81M.
A.I. Advisor
published General Information

General Information

a manufacturer of biopharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
2200 Pennsylvania Avenue NW
Phone
+1 202 734-3400
Employees
290
Web
https://www.vandapharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OSMCX34.41N/A
N/A
Invesco International Small-Mid Com C
NSGRX26.93N/A
N/A
Northern Small Cap Core I
CFXRX12.87N/A
N/A
Columbia Flexible Capital Income Inst2
HEORX14.30N/A
N/A
Hartford Climate Opportunities R3
BINAX8.89N/A
N/A
BlackRock Infrastructure Sust Opps Inv A

VNDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VNDA has been loosely correlated with ATRA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if VNDA jumps, then ATRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VNDA
1D Price
Change %
VNDA100%
+2.62%
ATRA - VNDA
43%
Loosely correlated
-9.85%
IKNA - VNDA
38%
Loosely correlated
-0.66%
AMLX - VNDA
38%
Loosely correlated
+2.90%
GOSS - VNDA
37%
Loosely correlated
+6.31%
MRNA - VNDA
37%
Loosely correlated
-2.02%
More

Groups containing VNDA

Correlation & Price change

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VNDA
1D Price
Change %
VNDA100%
+2.62%
drugs
(undefined stocks)
38%
Loosely correlated
-0.70%
biotechnology
(undefined stocks)
32%
Poorly correlated
-0.79%
biopharmaceuticals
(undefined stocks)
26%
Poorly correlated
+0.42%